CDC Expands HIV Treatment Access for Foreign Nationals in Taiwan

The Centers for Disease Control (CDC) in Taiwan announced plans to broaden access to publicly funded HIV treatment for foreign nationals beginning next year. CDC Director-General Philip Lo shared the update during a press conference, indicating that the revisions to subsidy regulations aim to enhance eligibility for foreign residents.

Initially, the expanded access will prioritize foreign nationals who hold permanent residency and those under the age of 18. However, additional details regarding the specific implementation of this expansion have yet to be disclosed. When the CDC was asked how many more foreign nationals would qualify for treatment under this new plan, officials stated they were still evaluating the potential impact and did not have a definitive figure.

Currently, the CDC supports the costs of HIV medication for the first two years of treatment for qualifying patients. After this period, expenses transition to be covered by the National Health Insurance (NHI) system. As of late last month, 36,494 Taiwanese nationals and 615 foreign nationals in Taiwan have been diagnosed with HIV. Among these foreign nationals, 343 are already covered under the NHI system, while others have been on medication for less than two years and do not yet qualify. Some of these individuals have received financial assistance through alternative means.

The treatment provided involves highly active antiretroviral therapy, often referred to as “cocktail therapy,” which employs a combination of at least two to three antiretroviral drugs. The monthly costs for medication are capped at NT$13,200.

Expanding Preventive Measures and Additional Programs

In conjunction with the changes to HIV treatment access, the CDC plans to increase the enrollment quota for the publicly funded HIV pre-exposure prophylaxis (PrEP) program to 9,500 participants from 8,000 this year. This program aims to prevent new HIV infections and is available to both Taiwanese citizens and their foreign spouses who meet specific criteria and have been assessed by healthcare professionals.

Lo noted that Taiwan is projected to experience approximately 850 new HIV cases in 2023, marking the lowest incidence rate since 2003 and a decrease of around 11% to 12% from the previous year, partly attributed to the effectiveness of the PrEP program.

Other initiatives will also roll out in 2024. These include expanded fertility subsidies for women enrolled in social insurance, including foreign spouses of Taiwanese citizens. The new subsidy will offer NT$100,000 per child, with increased amounts available for multiple births.

Additionally, a new adult pneumococcal vaccine program is set to commence on January 15, 2024, targeting individuals aged 65 or older, indigenous people aged 55 to 64, and high-risk individuals aged 19 to 64. This public subsidy program will allow individuals to save about NT$4,500 in out-of-pocket costs.

From now until February 28, 2024, the scope of free public COVID-19 vaccinations will expand to include anyone aged six months or older who has not yet received the vaccine. Currently, the private cost of the COVID-19 vaccine is at least NT$4,000. Furthermore, a nationwide gastric cancer screening initiative will be introduced, offering a one-time Helicobacter pylori screening for individuals aged 45 to 79.

These measures reflect the CDC’s commitment to enhancing public health services and support for both residents and foreign nationals in Taiwan.